Here’s a roundup of recent clinical trial news:
Clinical Trials
Clinical trial roundup: Medtronic revises CoreValve pivotal trial
Here’s a roundup of recent clinical study and clinical trial news:
Clinical studies roundup: Survival rates improving for some heart attacks
Here’s a roundup of recent clinical study and trial news:
Clinical trials roundup: Accuray touts CyberKnife prostate radiosurgery results
Here’s a roundup of recent clinical trial news:
RedOak Logic looking to drum up $3 million
A clinical trials software startup in Cary, N.C., is in the midst of developing its prototype and plans a $3 million fund-raise early next year.
RedOak Logic is creating digital clinical trials software but with a dimension of intelligence that can, among other things, pinpoint anomalies in trial subjects down to the genetic level, and contrast large amounts of trial data from virtually any type of public data. “We even threw in the Dow Jones Industrial Average” in one test, company founder Dale Fedewa said.
Sleep apnea device boosts energy
Individuals with obstructive sleep apnea may have a new therapy to relieve their symptoms of fatigue, a study shows.
Researchers at the University of California, Davis and San Diego State University tested a medical device that applies a therapy called "continuous positive airway pressure" on 59 men and women suffering from the condition. All were in their late 40s and experienced at least 10 partial or complete pauses, or apneas, during an hour of sleep.
Clinical studies roundup: Medtronic launches CoreValve trial
Here’s a roundup of recent clinical trial and scientific study news:
Clinical studies roundup: Scientists create functioning intestinal tissue from stem cells
Here’s a roundup of recent clinical trial and scientific study news:
Clinical trials roundup: Tryton wins conditional IDE nod
Here’s a roundup of recent clinical trial news:
Over-eager docs prompt Abiomed to halt Protect II trial
Over-ambitious doctors seem to have prompted Abiomed Inc. (NSDQ:ABMD) to close down a clinical trial of its flagship cardiac assist device.
The Danvers, Mass.-based company pulled the plug on the Protect II trial of its Impella 2.5 heart pump “based on a futility determination at the planned interim analysis regarding the primary end-point, which the company views as likely to be due to unanticipated confounding variables related to the use of rotational atherectomy,” according to a press release.
Clinical Update: A gap in the FDA’s oversight of medical device trials
There’s a “potentially troubling gap” in the Food & Drug Administration’s oversight of medical device clinical trials, according to the Wall Street Journal — the federal watchdog agency doesn’t inspect device-making plants during trials.
The Journal, citing the failed clinical trial of an Aptus Endosystems Inc. stent graft, said the lack of oversight means “hundreds of participants in clinical-trial studies of medical devices may be at risk of receiving faulty devices.”